Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q3 2026 · 10-Q
Revenue$0.00$0.00derived— vs Q3 2025 Net Income-$7.73M-$7.73MN/M vs Q3 2025 EPS Diluted-$0.06-$0.06N/M vs Q3 2025 Operating Income-$8,365,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Operating Cash Flowderived-$6,084,000N/M Free Cash Flowderived-$6,095,000N/M ended Mar 31, 2026 · filed May 12, 2026 · 42 d after period end